Please assess the completion status of the following clinical trial:

Trial Title: Novel Compositions for Treating or Preventing Dermal Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~Exclusion Criteria:~* Individuals with any chronic disease will be excluded from the study including those with the following conditions:~  * Diabetes~ * Any type of Malignancy~ * Severe coronary artery disease~ * HIV infection~ * Hepatitis C or B~ * Any sign of skin disorder or disease aside from normal aging, dermal atrophy, or seborrheic keratoses.~ * Premenopausal women will be excluded~ * Patients taking the following medications will be excluded:~ * Cyclosporin~ * Calcium channel blockers: diltiazem, verapamil~ * Antifungal agents e.g. clotrimazole, fluconazole, itraconazole~ * Antibiotics: clarithromycin, erythromycin, rifampicin~ * Anticonvulsants: carbamazepine, phenobarbitone, phenytoin~ * Antinausea drugs e.g. metoclopramide~ * Other drugs e.g. danazol, protease inhibitors (e.g. for HIV and hepatitis C including ritonavir, indinavir, boceprevir, and telaprevir)~ * Grapefruit juice~ * St John's wort (Hypericum perforatum, hypericin)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Rapamycin (Type: EXPERIMENTAL): Rapamycin

Based on this trial design, predict the completion outcome and termination type (if applicable).